Sargramostim is a human recombinant Granulocyte-macrophage colony-stimulating factor (GM-CSF) that is clinically used for cancer or post-transplantation therapy and is currently in an early-phase clinical investigation for PD (NLM Identifier: NCT03790670). The gene discussed is CSF2; the disease is cancer.